AptarGroup, Inc.’s (ATR - Free Report) Aptar Digital Health announced it signed an enterprise agreement with Biogen Inc. (BIIB - Free Report) to operate and develop digital health solutions for neurological and rare diseases.
This move will allow AptarGroup to strengthen its role as a go-to partner for the pharmaceutical industry, providing a full portfolio of device solutions, services and technology to help enhance the lives of patients worldwide.
As part of the deal, BIIB will transfer the ownership of certain digital health solutions to Aptar Digital Health. AptarGroup will provide Biogen with a comprehensive range of services, including product management, software design, development, and maintenance, secure cloud hosting, and customer and marketing support.
Biogen has successfully developed numerous flagship digital health products that have helped patients in more than 15 countries over the years. Aptar Digital Health's activities in neurology and immunology, which are two strategic therapeutic areas, will expand considerably under this collaboration.
AptarGroup's first solutions for operations in North America, Europe/the U.K., the Asia Pacific, and Latin America include Cleo/Aby and Physio.me. In addition to these solutions, Biogen and AptarGroup will work to develop and sell digital health solutions for the management of spinal muscular amyotrophy, Friedreich's ataxia and lupus in certain countries.
AptarGroup reported fourth-quarter 2023 adjusted earnings per share of $1.21, beating the Zacks Consensus Estimate of $1.12. The bottom line increased 27% from the 95 cents per share (including comparable exchange rates) reported in the year-ago quarter.
Total revenues increased 5.3% year over year to $838 million in the reported quarter. The top line surpassed the Zacks Consensus Estimate of $832 million.
Price Performance
Shares of the company have gained 28.3% in the past year compared with the industry’s 0.2% rise.
Zacks Rank and Stocks to Consider
AptarGroup currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the Industrial Products sector are Cadre Holdings, Inc. (CDRE - Free Report) and AZZ Inc. (AZZ - Free Report) . CDRE currently sports a Zacks Rank #1 (Strong Buy) and AZZ carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Cadre Holdings’ 2024 earnings is pegged at $1.11 per share. The consensus estimate for 2024 earnings has moved 1% north in the past 60 days and suggests year-over-year growth of 16.7%. The company has a trailing four-quarter average earnings surprise of 33%. CDRE shares have gained 49.2% in the past year.
The Zacks Consensus Estimate for AZZ’s fiscal 2024 earnings per share is pegged at $4.19. The consensus estimate for 2024 earnings has moved 2% north in the past 60 days. The company has a trailing four-quarter average earnings surprise of 37.6%. AZZ shares have rallied 51.8% in the past year.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
AptarGroup, Inc.’s (ATR - Free Report) Aptar Digital Health announced it signed an enterprise agreement with Biogen Inc. (BIIB - Free Report) to operate and develop digital health solutions for neurological and rare diseases.
This move will allow AptarGroup to strengthen its role as a go-to partner for the pharmaceutical industry, providing a full portfolio of device solutions, services and technology to help enhance the lives of patients worldwide.
As part of the deal, BIIB will transfer the ownership of certain digital health solutions to Aptar Digital Health. AptarGroup will provide Biogen with a comprehensive range of services, including product management, software design, development, and maintenance, secure cloud hosting, and customer and marketing support.
Biogen has successfully developed numerous flagship digital health products that have helped patients in more than 15 countries over the years. Aptar Digital Health's activities in neurology and immunology, which are two strategic therapeutic areas, will expand considerably under this collaboration.
AptarGroup's first solutions for operations in North America, Europe/the U.K., the Asia Pacific, and Latin America include Cleo/Aby and Physio.me. In addition to these solutions, Biogen and AptarGroup will work to develop and sell digital health solutions for the management of spinal muscular amyotrophy, Friedreich's ataxia and lupus in certain countries.
AptarGroup reported fourth-quarter 2023 adjusted earnings per share of $1.21, beating the Zacks Consensus Estimate of $1.12. The bottom line increased 27% from the 95 cents per share (including comparable exchange rates) reported in the year-ago quarter.
Total revenues increased 5.3% year over year to $838 million in the reported quarter. The top line surpassed the Zacks Consensus Estimate of $832 million.
Price Performance
Shares of the company have gained 28.3% in the past year compared with the industry’s 0.2% rise.
Zacks Rank and Stocks to Consider
AptarGroup currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the Industrial Products sector are Cadre Holdings, Inc. (CDRE - Free Report) and AZZ Inc. (AZZ - Free Report) . CDRE currently sports a Zacks Rank #1 (Strong Buy) and AZZ carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Cadre Holdings’ 2024 earnings is pegged at $1.11 per share. The consensus estimate for 2024 earnings has moved 1% north in the past 60 days and suggests year-over-year growth of 16.7%. The company has a trailing four-quarter average earnings surprise of 33%. CDRE shares have gained 49.2% in the past year.
The Zacks Consensus Estimate for AZZ’s fiscal 2024 earnings per share is pegged at $4.19. The consensus estimate for 2024 earnings has moved 2% north in the past 60 days. The company has a trailing four-quarter average earnings surprise of 37.6%. AZZ shares have rallied 51.8% in the past year.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on BIIB - FREE
Get the latest research report on AZZ - FREE
Get the latest research report on ATR - FREE
Get the latest research report on CDRE - FREE